Clinical Trial Update: An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies [Phase 1]

View source ↗

Summary

This open-label Phase 1 pilot study assessed the safety and potential efficacy of rituximab in patients with granulomatosis with polyangiitis (Wegener's granulo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Wegener's Granulomatosis | Phase 1 | Status: COMPLETED